Skip to content Skip to footer
Subscribe Now

INSIGHTS+

PharmaShots' Key Highlights of First Quarter 2023
PharmaShots’ Key Highlights of First Quarter 2023
Shots: The first quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Meanwhile, Selecta and Sobi reported P-III trial (DISSOLVE I & II) results of SEL-212 for chronic refractory gout Starting with the latest acquisitions, Pfizer acquired Seagen for ~$43B. The first quarter of the year also showcases…
April 3, 2023
Insights+: EMA Marketing Authorization of New Drugs in February 2023
Insights+: EMA Marketing Authorization of New Drugs in February 2023
Shots: The EMA approved 7 New Chemical Entity (NCE) and 5 Biologic Drugs in February 2023, leading to treatments for patients and advances in the healthcare industry In February 2023, the major highlights drugs were Forxiga’s Approval for symptomatic chronic heart failure, Fintepla for adjunctive treatment of seizures associated with lennox-gastaut syndrome PharmaShots has compiled…
March 23, 2023
Top Performing Drug of 2021 - Darzalex (March Edition)
Top Performing Drug of 2021 – Darzalex (March Edition)
Shots: The ongoing series of the top-performing drugs of 2021 based on revenue is continued by Darzalex as the top-performing drug for March month Darzalex is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma in combination with different drugs The report summarizes the key features of Darzalex including revenue…
March 21, 2023
Insights+: The US FDA New Drug Approvals in February 2023
Insights+: The US FDA New Drug Approvals in February 2023
Shots: The US FDA approved 5 NDAs and 5 BLA in February 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 19 novel products in 2023 In February 2023, the major highlights drugs were, Tezspire (tezepelumab) approval for severe asthma, Altuviiio for hemophilia A PharmaShots has compiled…
March 15, 2023
Disease of the Month: IgA Nephropathy
Disease of the Month: IgA Nephropathy
Shots: To create a wholesome environment for the current and the future generation, it’s totally up to life science companies and decision-makers to embrace and integrate every prospect of the underlying disease conditions and address those issues to find cures PharmaShots brings this month an informative take on the disease IgA nephropathy Often known as…
March 13, 2023
Insights+ Key Biosimilars Events of February 2023
Insights+ Key Biosimilars Events of February 2023
Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of February, Alvotech entered into a commercialization agreement…
March 1, 2023
Insights+ Key Biosimilars Events of February 2023
Insights+: EMA Marketing Authorization of New Drugs in January 2023
Shots: The EMA approved 3 New Chemical Entity (NCE) and 5 Biologic Drugs in January 2023, leading to treatments for patients and advances in the healthcare industry In January 2023, the major highlights drugs were Xofluza’s Approval for influenza, Dupixent for eosinophilic esophagitis PharmaShots has compiled a list of a total of 8 new drugs…
February 23, 2023
Top Performing Drug of 2021 - Trulicity (February Edition)
Top Performing Drug of 2021 – Trulicity (February Edition)
Active Ingredient: dulaglutide Dosage Forms & Strengths:   Injection: 0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, 4.5 mg/0.5 mL solution in a single-dose pen   Mechanism of Action: GLP-1 receptor agonist First Approval: US (Sep 18, 2014), EU (Nov 25, 2014)   Revenue Analysis1 Trulicity is used for the treatment of type 2 diabetes and to reduce the risk…
February 22, 2023
Insights+: The US FDA New Drug Approvals in January 2023
Insights+: The US FDA New Drug Approvals in January 2023
Shots: The US FDA approved 8 NDAs and 1 BLA in January 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 9 novel products in 2023 In January 2023, the major highlights drugs were Rykindo (risperidone) approval for schizophrenia and bipolar 1 disorder, Brenzavvy (bexagliflozin) for type…
February 15, 2023
Disease of the Month: Age-Related Macular Degeneration
Disease of the Month: Age-Related Macular Degeneration
Introduction: AMD, an eye disease that can cause of loss of eyesight/blur vision mostly in people ≥50 years of age and it is the leading cause of visual impairment worldwide. It occurs when the part of the retina (macula) is damaged. Patients lose their central vision and cannot see fine details The three stages of…
February 9, 2023
Load more